| Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa, P Tracy, N Feeney, ... JAMA oncology 4 (11), 1527-1534, 2018 | 623 | 2018 |
| Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer AG Sacher, C Paweletz, SE Dahlberg, RS Alden, A O’Connell, N Feeney, ... JAMA oncology 2 (8), 1014-1022, 2016 | 610 | 2016 |
| False-positive plasma genotyping due to clonal hematopoiesis Y Hu, BC Ulrich, J Supplee, Y Kuang, PH Lizotte, NB Feeney, NM Guibert, ... Clinical Cancer Research 24 (18), 4437-4443, 2018 | 387 | 2018 |
| Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium BT Li, F Janku, B Jung, C Hou, K Madwani, R Alden, P Razavi, ... Annals of Oncology 30 (4), 597-603, 2019 | 140 | 2019 |
| Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes PH Lizotte, EV Ivanova, MM Awad, RE Jones, L Keogh, H Liu, R Dries, ... JCI insight 1 (14), 2016 | 138 | 2016 |
| Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer N Guibert, Y Hu, N Feeney, Y Kuang, V Plagnol, G Jones, K Howarth, ... Annals of Oncology 29 (4), 1049-1055, 2018 | 135 | 2018 |
| A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II … M Yanagita, AJ Redig, CP Paweletz, SE Dahlberg, A O'Connell, N Feeney, ... Clinical Cancer Research 22 (24), 6010-6020, 2016 | 119 | 2016 |
| Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients Y Hu, RS Alden, JI Odegaard, SR Fairclough, R Chen, J Heng, N Feeney, ... Clinical Cancer Research 23 (23), 7351-7359, 2017 | 76 | 2017 |
| OA 09.02 osimertinib resistance mediated by loss of EGFR T790M Is associated with early resistance and competing resistance mechanisms G Oxnard, Y Hu, K Mileham, P Tracy, N Feeney, L Sholl, C Paweletz, ... Journal of Thoracic Oncology 12 (11), S1767-S1768, 2017 | 19 | 2017 |
| Abstract CT046: Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with RAS mutant … GI Shapiro, J Hilton, L Gandi, N Chau, J Cleary, A Wolanski, A Anderson, ... Cancer Research 77 (13_Supplement), CT046-CT046, 2017 | 15 | 2017 |
| Prospective validation of rapid plasma genotyping as a sensitive and specific tool for guiding lung cancer care AG Sacher, C Paweletz, SE Dahlberg, RS Alden, A O’Connell, N Feeney, ... JAMA oncology 2 (8), 1014, 2016 | 13 | 2016 |
| Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with … NM Guibert, C Paweletz, Y Hu, NB Feeney, V Plagnol, V Poole, G Jones, ... Journal of Clinical Oncology 35 (15_suppl), 11529-11529, 2017 | 11 | 2017 |
| Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016; 2 (8): 1014–22 AG Sacher, C Paweletz, SE Dahlberg, RS Alden, A O’Connell, N Feeney | 10 | 2016 |
| Monitoring of response and resistance in plasma of EGFR-mutant lung cancer using droplet digital PCR Y Kuang, A O’Connell, AG Sacher, N Feeney, RS Alden, GR Oxnard, ... Digital PCR: Methods and Protocols, 193-207, 2018 | 5 | 2018 |
| Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC GR Oxnard, Y Hu, P Tracy, N Feeney, CP Paweletz, KS Thress, PA Janne Cancer Research 77 (13_Supplement), 4112-4112, 2017 | 3 | 2017 |
| Serial droplet digital PCR (ddPCR) of plasma cell-free DNA (cfDNA) as pharmacodynamic (PD) biomarker in Phase 1 clinical trials for patients (pts) with KRAS mutant non-small … CP Paweletz, GR Oxnard, N Feeney, JF Hilton, L Gandhi, KT Do, ... Cancer Research 76 (14_Supplement), 3157-3157, 2016 | 3 | 2016 |
| Utilizing NSCLC PDXs derived from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies S Palakurthi, M Xu, AJ Redig, M Dills, P Gokhale, J Choi, A Ogino, ... Cancer Research 76 (14_Supplement), 5192-5192, 2016 | 1 | 2016 |
| P3. 02-014 Amplicon-Based Next-Generation Sequencing (NGS) of Plasma Cell-Free DNA (cfDNA) for Detection of Driver and Resistance Mutations in NSCLC N Guibert, Y Hu, N Feeney, E Michael, S Woodhouse, K Howarth, ... Journal of Thoracic Oncology 12 (11), S2243, 2017 | | 2017 |
| Clinical Validation of Plasma Cell Free DNA Mutation Detection in Patients with EGFR-Mutated Lung Cancer LM Sholl, JL Bruce, RS Alden, CA Lydon, NB Feeney, CP Paweletz, ... JOURNAL OF MOLECULAR DIAGNOSTICS 18 (6), 1026-1027, 2016 | | 2016 |
| Predictors of High Levels of Mutant cfDNA in Plasma from Patients with Advanced Lung Adenocarcinoma LM Sholl, P Pal, RS Alden, N Feeney, C Paweletz, A Sacher, GR Oxnard LABORATORY INVESTIGATION 96, 483A-483A, 2016 | | 2016 |
